The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final overall survival from a phase 3 trial of nab-paclitaxel versus dacarbazine (DTIC) in chemotherapy-naive patients with metastatic melanoma.
Evan Hersh
Research Funding - Celgene
Michele Del Vecchio
Research Funding - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Roche
Michael Paul Brown
Consultant or Advisory Role - Celgene
Richard Kefford
No relevant relationships to disclose
Carmen Loquai
Honoraria - Bristol-Myers Squibb
Alessandro Testori
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Roche
Honoraria - Bristol-Myers Squibb
Shailender Bhatia
No relevant relationships to disclose
Ralf Gutzmer
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Novartis; Roche
Honoraria - Almirall Hermal GmbH; Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Pharmaceutical ; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Research Funding - Novartis; Pfizer; Roche
Other Remuneration - Bristol-Myers Squibb; Roche
Andrew Mark Haydon
No relevant relationships to disclose
Caroline Robert
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; R and D; Roche
Mingyu Li
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Ileana Elias
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Markus Frederic Renschler
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Axel Hauschild
Consultant or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche
Research Funding - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche